Official Title: “Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function”

We test the hypothesis that different beta-blockers had a different influence on chemoreceptor response and lung diffusion capacity.

Both could influence exercise capacity in normoxic as well as hypoxic conditions.

Study Type: Interventional

Study Design: Treatment, Randomized, Single Blind (Investigator), Active Control, Crossover Assignment, Efficacy Study

Intervention(s) in this Clinical Trial

• Drug: carvedilol
• Drug: bisoprolol
• Drug: Nebivolol

Arms, Groups and Cohorts in this Clinical Trial

• Active Comparator: Carvedilol
• Active Comparator: Bisoprolol
• Active Comparator: Nebivolol

Primary Measures

• exercise capacity
  • Time Frame: two months
    

Secondary Measures

• lung diffusion
  • Time Frame: two months
    

Inclusion Criteria:

• Chronic heart failure patients in stable clinical condition

Exclusion Criteria:

• No comorbidity
• NYHA class IV

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 80 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Centro Cardiologico Monzino

Overall Clinical Trial Officials and Contacts

Piergiuseppe Agostoni, MD, PhD Principal Investigator Centro Cardiologico Monzino  

Overall Contact: Piergiuseppe Agostoni, MD, PhD +39.025800 piergiuseppe.agostoni@ccfm.it

Information obtained from ClinicalTrials.gov on January 08, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00517725

Study ID Number: R76-CCM S78/407

ClinicalTrials.gov Identifier: NCT00517725

Health Authority: Italy: Ministry of Health